背景:人类细胞色素P450(CYP)超家族包括不同类别的同工酶,这些同工酶有助于涉及药物解毒的多种代谢过程,细胞信号,和恶性组织的增殖。利用基因技术,定制的生物信息学分析,和荟萃分析设计,本研究的主要目的是确定CYP1A2*rs762551变异体与乳腺癌(BRCA)易感性之间的关联.
方法:病例对照研究是基于104名BRCA妇女和102名健康对照进行的。使用TaqMan等位基因区分分析,对CYP1A2(rs762551;c.-9-154C>A)变体进行基因分型。使用生物信息学框架和逻辑回归分析来评估该遗传变异在BRCA发育中的参与。根据我们的病例对照研究和其他先前发表的记录,完成了荟萃分析设计。出版偏见,研究之间的异质性,和试验序贯分析(TSA)进行分析。
结果:CYP1A2*rs762551变体在等位基因(OR=0.48,p值<0.001)下赋予针对BRCA发展的保护作用,显性(OR=0.34,p值<0.001),和隐性(OR=0.44,p值=0.011)模型。然而,与其他病例相比,这一内含子变异与晚发型绝经女性的BRCA风险降低相关.生物信息学分析证实,这种遗传变异对肿瘤发生的进展具有功能影响。此外,这项荟萃分析设计包括12922名BRCA女性和15603名健康对照.我们的发现揭示了CYP1A2*rs762551变体在等位基因下对高加索女性癌症发展的保护作用(OR=0.75,p值=0.025),和显性(OR=0.58,p值=0.015)模型。
结论:这项病例对照研究证实了CYP1A2*rs762551变体在埃及受试者中具有降低BRCA发展风险的作用。此外,与其他受试者相比,具有晚发性绝经的BRCA女性赋予了针对癌症进展的保护。我们的发现发现,与其他种族相比,这种荟萃分析设计可以防止白种人女性的BRCA发展。
BACKGROUND: The human cytochrome P450 (CYP) superfamily encompasses different categories of isoenzymes that contribute to multiple metabolic processes involving drug detoxification, cellular signaling, and the proliferation of malignant tissues. Using genetic technology, customized bioinformatic analysis, and meta-analysis design, the main goal of this study was to identify the association between the CYP1A2*rs762551 variant and the susceptibility to breast carcinoma (BRCA).
METHODS: The
case-control study was conducted based on 104 BRCA women and 102 healthy controls. Using the TaqMan allelic discrimination assay, the CYP1A2 (rs762551; c.-9-154 C>A) variant was genotyped. Bioinformatic frameworks and logistic regression analysis were used to assess the involvement of this genetic variant in BRCA development. A meta-analysis design was accomplished based on our
case-control study and other previously published records. Publication bias, heterogeneity between studies, and trial sequential analysis (TSA) were analyzed.
RESULTS: The CYP1A2*rs762551 variant conferred protection against BRCA development under allelic (OR = 0.48, p-value < 0.001), dominant (OR = 0.34, p-value < 0.001), and recessive (OR = 0.44, p-value = 0.011) models. However, this intronic variant was correlated with a decreased risk of BRCA among late-onset menopause women compared to other cases. Bioinformatic analysis confirmed that this genetic variant has a functional impact on the progression of tumorgenesis. Moreover, this meta-analysis design included 12922 BRCA women and 15603 healthy controls. Our findings disclosed the contribution of the CYP1A2*rs762551 variant with protection against cancer development among Caucasian females under allelic (OR = 0.75, p-value = 0.025), and dominant (OR = 0.58, p-value = 0.015) models.
CONCLUSIONS: This
case-control study confirmed the contribution of the CYP1A2*rs762551 variant with decreased risk of BRCA development among Egyptian subjects. Moreover, BRCA women with late-onset menopause conferred protection against cancer progression compared to other subjects. Our findings identified that this meta-analysis design achieved protection against BRCA development among Caucasian women compared to other ethnicities.